Nitroglycerin Macure (Glyceryl Trinitrate)

After intravenous administration, glyceryl trinitrate is metabolized to nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. The resulting increase in cyclic GMP causes relaxation of veins and arteries, lowering preload and afterload and decreasing myocardial oxygen demand.

The specific dose and infusion rate of Nitroglycerin Macure are determined by the prescribing clinician based on the patient’s condition, response, and monitoring parameters. Healthcare professionals adjust the regimen to achieve desired hemodynamic effects while avoiding excessive hypotension.

The safety of glyceryl trinitrate in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and necessary import documentation.

Nitroglycerin Macure belongs to the organic nitrate class, providing rapid onset of vasodilation via nitric oxide release. Compared with beta‑blockers or calcium‑channel blockers, nitrates act directly on vascular smooth muscle and are especially useful for immediate relief of ischemic chest pain, whereas other classes may be used for longer‑term rate control or blood‑pressure management.

The product should be stored at ambient temperature, preferably below 25 °C, in its original container protected from light and moisture. Ensure the vial or ampoule is kept upright and avoid exposure to extreme temperatures to maintain stability.

Nitroglycerin Macure is administered intravenously, typically as a continuous infusion or intermittent bolus under close hemodynamic monitoring. The route allows rapid plasma concentrations, enabling quick therapeutic effects in emergency cardiovascular situations.

Serious risks include profound hypotension, which can lead to syncope or shock, and rare occurrences of methemoglobinemia or severe allergic reactions. Continuous blood‑pressure monitoring and readiness to intervene with fluids or vasopressors are essential during administration.

Patients with known hypersensitivity to nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe hypotension or cardiogenic shock should not receive Nitroglycerin Macure unless specifically directed by a physician.